Treatment with dupilumab is safe and effective for patients with bullous pemphigoid, with complete remission seen as early as 4 weeks of treatment.

Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of ...

Galderma has reported that the randomised Phase III OLYMPIA 1 trial, which evaluated the nemolizumab monotherapy in adult ...

Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of n ...

Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a ...

Topline results were announced from a phase 3 trial evaluating linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

An estimated 240,000 PBC patients will experience cholestatic pruritus by 2030. Credit: BSIP / Contributor / Getty images. GSK has announced positive headline results of its ongoing global Phase III ...

"We look forward to initiating a Phase 2 multiple-ascending dose trial in the coming months to evaluate TH104 in chronic pruritus in primary biliary cholangitis (PBC) patients, with topline data ...

Data presented at The Liver Meeting include adverse events as well as an assessment of patients’ relief of pruritus symptom scores when correlated to pharmacokinetics of TH104. Patients with ...

Itching (pruritus) is one symptom of chronic liver disease, though not everyone with liver disease develops it. You might have a localized itch, such as on your lower arm, or it might be an all ...

The late-breaking presentations (Abstract #5041 and Abstract #5042) report on biomarkers of cholestasis, stabilization of surrogate markers of liver fibrosis and moderate-to-severe pruritus data for ...